Case Report: From misdiagnosis to successful treatment using mepolizumab in ANCA-negative severe EGPA—clinical lessons in eosinophil-targeted therapy - Scorecard - MDSpire
Advertisement
Case Report: From misdiagnosis to successful treatment using mepolizumab in ANCA-negative severe EGPA—clinical lessons in eosinophil-targeted therapy
Clinical Scorecard: Clinical Insights: Transitioning from Misdiagnosis to Effective Management of ANCA-Negative Severe EGPA with Mepolizumab—Lessons in Eosinophil-Directed Therapy
At a Glance
Category
Detail
Condition
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Key Mechanisms
Involves eosinophilia and systemic necrotizing vasculitis affecting multiple organs.
Target Population
Patients with ANCA-negative severe EGPA, particularly those with multi-organ involvement.
Care Setting
Clinical management of severe systemic vasculitis.
Key Highlights
Mepolizumab effectively induced and maintained remission in a patient with ANCA-negative severe EGPA.
Initial treatment with omalizumab may mask disease progression in undiagnosed EGPA.
Mepolizumab dosing interval extended to 8 weeks showed sustained remission.
ANCA-negative EGPA often misdiagnosed as refractory asthma.
The patient exhibited multi-organ involvement including myocarditis and pericardial effusion.
Guideline-Based Recommendations
Diagnosis
Utilize the 2022 ACR/EULAR classification criteria for diagnosing EGPA.
Management
Consider mepolizumab for treatment in patients with severe EGPA.
Monitoring & Follow-up
Regularly assess eosinophil levels and monitor for disease progression.
Risks
Be cautious of initiating biologic therapy in patients with asthma without ruling out EGPA.
Patient & Prescribing Data
33-year-old female with a history of allergic rhinitis and asthma.
Mepolizumab was initiated after failure of omalizumab, leading to symptom resolution.
Clinical Best Practices
Evaluate for EGPA in patients with asthma and eosinophilia before starting biologic therapy.
Monitor for potential complications such as myocarditis in patients with severe EGPA.
